Novel Disease Mechanisms for Respiratory or Cardiovascular or Renal Disease or Diabetes using tool pre-clinical compounds - Biowebspin | Biowebspin
Logo Biowebspin

Biowebspin : THE #1 ACADEMIA-INDUSTRY PARTNERING NETWORK FOR SCIENTIFIC INNOVATIONS

The worldwide platform to find industrial partners and funding

External open innovation partner programNovel Disease Mechanisms for Respiratory or Cardiovascular or Renal Disease or Diabetes using tool pre-clinical compounds
Pharmaceutical R&D face several significant challenges in terms identifying drug targets that translate from basic science into clinical projects and then ultimately into medicines that make a difference to the lives of patients. The availability of high-quality tool compounds enables potential mechanism(s) of disease to be investigated that may provide novel insights into the biology of the disease and hopefully better translation into the clinic.
What we are looking for

AstraZeneca is seeking proposals that probe novel mechanism of disease for a subset of human disease, respiratory, cardiovascular, renal and diabetes by providing a selection of high-quality tool compounds. These compounds provide valuable opportunities to explore disease biology in the pre-clinical setting. Please, contact us to receive the list of tool compounds and their respective target.
The expected deliverable is a proposal that presents a sound scientific rationale that links one or more of the tool compounds to a specific mechanism/insight of disease. It is expected that the rationale that links the compound to a disease mechanism/insight can be tested experimentally, and therefore, it can be translated into clinical studies in due course. The proposed mechanism being investigated must include at least one compound selected from the AstraZeneca pre-clinical tool compound list. The disease indication must fall within one of the following therapeutic areas; respiratory disease (lung epithelium, lung immunity and lung regeneration) or cardiovascular disease or metabolic disease (Type 2 diabetes, heart failure, NASH and chronic kidney disease) to be considered.

What we offer and how does it work

The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive the full award the Solvers, need to agree that the Seeker has the right to negotiate a non-exclusive license to the novel mechanism/insight of the disease.

Proponents that submit proposals of interest will be contacted within 8 weeks of submission to clarify additional details.

What to submit

This is a Theoretical Challenge that requires only a written proposal to be submitted that links a target/tool compound to a novel mechanism/insight of disease.

Submit a proposal in a form which is available online (it takes about 15 minutes).The proposal should be brief, sufficient to provide the main body of the proposal and its innovativeness. The applicant should also provide information about his or her critical knowledge that is applicable for the proposal, and how the knowledge could be supplemented (i.e., what is additionally required to complete the project). The applicants are strongly encouraged to give us additional information including references or other materials to facilitate the evaluation process.

Privacy, confidentiality & FAQ Astrazeneca

The Company will not share the information beyond its own staff; your initial proposal should contain only non-confidential information.
If your proposal is selected, the Company is open to complete a Confidentiality Disclosure Agreement (CDA).

Biowebspin

Biowebspin pays a lot of attention to the privacy, intellectual property, confidentiality and security of its member data. Biowebspin is a matchmaking platform between academia & industry. Biowebspin is not involved in the IP discussion and is not charging any success or license fees. Your «Open Innovation» opportunities on Biowebspin are only visible by industrials and the Biowebspin team. You can remove your data at any time. Biowebspin strongly recommends that you do not enter any confidential data or if you do so, that your technology transfer office agrees the submission of your pre-proposal on Biowebspin. If you directly submit your pre-proposal on an industrial partner website, you will agree their terms, conditions and privacy policy of our industrial partner website. Biowebspin is not responsible for the content, accuracy, or opinion of its industrial partner website. As a Swiss International company, Biowebspin has high standard security and privacy system. Biowebspin is in accordance with the Federal Data Protection and Information Commissioner. Contact us for more information about the terms and conditions of the matchmaking service of Biowebspin.

Astrazeneca

AstraZeneca is a global, science-led, biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular & Metabolic Diseases and Respiratory. AstraZeneca also is selectively active in the areas of autoimmunity, neuroscience and infection.